A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Open Access
- 14 March 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Abstract
Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179). For each plasma biomarker, cutoffs were determined for 90%, 95%, or 97.5% sensitivity to detect tau-PET-positivity. We calculated the percentage of patients below the cutoffs (who would not undergo tau-PET; “saved scans”) and the tau-PET-positivity rate among participants above the cutoffs (who would undergo tau-PET; “positive predictive value”). Generally, plasma pTau217 performed best. At the 95% sensitivity cutoff in both cohorts, pTau217 resulted in avoiding nearly half tau-PET scans, with a tau-PET-positivity rate among those who would be referred for a scan around 70%. And although tau-PET was strongly associated with subsequent cognitive decline, in BioFINDER-2 it predicted cognitive decline only among individuals above the referral cutoff on plasma pTau217, supporting that this workflow could reduce prognostically uninformative tau-PET scans. In conclusion, plasma pTau217 may guide selection of patients for tau-PET, when accurate prognostic information is of clinical value.Keywords
Funding Information
- Vetenskapsrådet (2022-00775)
- Alzheimerfonden (AF-980907)
This publication has 50 references indexed in Scilit:
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Effect of Neprilysin Inhibition on Alzheimer Disease Plasma BiomarkersJAMA Neurology, 2024
- Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive SymptomsJAMA Neurology, 2023
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJAMA Neurology, 2023
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumJAMA Neurology, 2021
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseJAMA Neurology, 2021
- Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative DisordersJAMA Neurology, 2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer DiseaseJAMA Neurology, 2019
- Diagnostic Criteria for Parkinson DiseaseArchives of Neurology, 1999